Table 2 Data regarding mastectomy and lymph node surgery
THERAPEUTIC ME INDICATION | PROPHYLACTIC ME INDICATION | ||||
|---|---|---|---|---|---|
NO IBLR or NP (DF-cohort) 87 patients/ 108 breasts | WITH IBLR/NP (D-cohort) 18 patients/ 18 breasts | p-VALUE | NO NP (DF-cohort) 29 patients/ 54 breasts | WITH NP (D-cohort) 1 patient/ 1 breast | |
Mastectomy typePB | |||||
- Simple mastectomy (SME) | 64 (59.3%) | 10 (55.6%) | .201 | 6 (11.1%) | 1 (100%) |
- Nipple-sparing mastectomy (NSM) | 24 (22.2%) | 7 (38.9%) | .201 | 35 (64.8%) | 0 |
- Skin-sparing mastectomy (SSM) | 20 (18.5%) | 1 (5.6%) | .201 | 13 (24.1%) | 0 |
Mastectomy indicationPB | |||||
- Oncologic | |||||
- Primary breast cancer | 102 (94.4%) | 15 (83.3%) | .119 | ||
- Breast cancer recurrence | 6 (5.6%) | 3 (16.7%) | .119 | ||
- Prophylactica | 16 (14.8%) | 6 (33.3%) | .087 | ||
- HBOC | 16 (14.8%) | 6 (33.3%) | .087 | 38 (70.4%) | 0 |
- Mantle-field radiation | 0 | 0 | 2 (3.7%) | 0 | |
- Undefined | 0 | 0 | 14 (25.9%) | 1 (100%) | |
ME volume (median cc, IQR)PB | 455 (350;550) | 305 (260;350) | .208 | 351 (181.5; 462.0) | NA |
Lymph node surgeryPB | 95 (90.5%) | 14 (87.5%) | .659 | ||
- Sentinel node | 45 (42.9%) | 6 (37.5%) | |||
- Axillary dissection | 50 (47.6%) | 8 (50.0%) | |||